Trial of a selective acetylcholinesterase inhibitor, galanthamine hydrobromide, in the treatment of chronic fatigue syndrome. Journal of Chronic Fatigue Syndrome 1996; 2(2/3): 35-54.
Efficacy of a half dose of oral pyridostigmine in the treatment of chronic fatigue syndrome: three case reports.
These studies indicate that acetylcholinesterase inhibitors can improve the symptoms of chronic fatigue syndrome and fibromyalgia. These medications are used to treat Alzheimer’s disease and myasthenia gravis by increasing acetylcholine in the central nervous system. There is evidence that chronic EBV, CMV and HHV-6 infections can block the acetylcholine transmission, resulting in cognitive (memory) problems, muscle weakness, fatigue and depression. After 8 weeks of treatment with this medication, significant improvements were demonstrated in sleep, fatigue, muscle pain and dizziness. This is another medication that can be included in the arsenal of medications and can be used on an individualized basis with a comprehensive approach in the treatment of chronic fatigue syndrome and fibromyalgia.